Translational Pharmacology and Early Therapeutic Trials

$85,483P30FY2013CANIH

Dana-Farber Cancer Inst, Boston MA

Investigators

Linked publications, trials & patents

Paper 39713466 Paper 39666914 Paper 39605676 Paper 39593217 Paper 39536083 Paper 39532885 Paper 39484503 Paper 39389170 Paper 39322760 Paper 39168126 Paper 39160372 Paper 39107288 Paper 39042477 Paper 39025073 Paper 39024561 Paper 38996877 Paper 38992034 Paper 38979326 Paper 38979245 Paper 38942046 Paper 38924531 Paper 38889153 Paper 38861327 Paper 38815709 Trial NCT03029325 Trial NCT02627430 Trial NCT02142803 Trial NCT02097225 Trial NCT02079740 Trial NCT01940809 Trial NCT01835184 Trial NCT01822509 Trial NCT01575522 Trial NCT01434316 Trial NCT01307631 Trial NCT01283035 Trial NCT01116648 Trial NCT01026324 Trial NCT00956163 Trial NCT00888134 Trial NCT00662506 Trial NCT00622401 Trial NCT00458978 Trial NCT00458549 Trial NCT00429910 Trial NCT00400946 Trial NCT00376480 Trial NCT00357500 Trial NCT00301093 Trial NCT00126672 Trial NCT00101075 Trial NCT00098865 Trial NCT00098514 Trial NCT00096291 Trial NCT00095927 Trial NCT00095901 Trial NCT00095875 Trial NCT00095836 Trial NCT00090857 Trial NCT00084838 Trial NCT00083031 Trial NCT00079326 Trial NCT00072436 Trial NCT00069940 Trial NCT00053976 Trial NCT00052611 Trial NCT00047294 Trial NCT00047281 Trial NCT00020670 Trial NCT00020605 Trial NCT00007917 Trial NCT00006107 Trial NCT00005988 Trial NCT00005096 Trial NCT00004180 Trial NCT00004163 Trial NCT00004070 Trial NCT00003761 Trial NCT00003744 Trial NCT00003657 Trial NCT00003200 Trial NCT00003058 Trial NCT00003045 Patent 9512485 Patent 7786269 Patent 7396678 Patent 7229755 Patent 7048929 Patent 6908617 Patent 6479284 Patent 6479281 Patent 5861424 Patent 5670530 Patent 5618831 Patent 5502214 Patent 5360803 Patent 4625014 Patent 4618492 Patent 4542225 Patent 4035566

Abstract

PROJECT SUMMARY (See instructions): The capability to develop new anti-cancer agents is essential to the mission of the Cancer Center. The Translational Pharmacology and Early Therapeutic Trials (TPETT) Program accomplishes this by: 1)supporting the preclinical development of anti-cancer agents identified by DF/HCC investigators, and 2)defining the toxicity, pharmacokinetics and pharmacodynamics of new agents from the Center, NCI and pharmaceutical companies In Early Phase trials. The overall objective of the TPETT Program is, thus, to foster a coordinated effort: through which promising new leads and agents are developed for evaluation in Early Phase clinical trials and then in Phase 11 in conjunction with the Clinical-based Programs. The Program facilitates the development of anti-cancer agents by combining basic science and clinical resources at the DFCI, MGH, BWH, BIDMC and CHB. Its Specific Aims are to: 1) strengthen and expand preclinical drug discovery and development efforts; 2) perform translational studies to identify responsive subsets of tumors and confirm mechanism of action in the clinic; 3) conduct Phase I, l-ll pharmacokinetic/pharmacodynamic trials of new anti-cancer agents with correlative laboratory and imaging studies to define biological endpoints and mechanisms; and 4) develop biomarkers for drug response, resistance and toxicity. The 49 members of this program represent six DF/HCC institutions and eight departments of HMS. In 2009, members received $10.4 million (total costs) in cancer-relevant funding, including $2.7 million from NCI and $370,000 from other peer-reviewed sponsors. In addition, members published 500 papers during the project period (2006 to 2010), of which 12.4% were intra-programmatic, 50% were inter-programmatic, and 25.4% were inter-institutional. The Program has been continuously funded as a CCSG Program for ten years. At the time of the last competitive renewal in 2005, the Program received Excellent merit.

View original record on NIH RePORTER →